Literature DB >> 11826285

Molecular pathogenesis of lung cancer.

Sabine Zochbauer-Muller1, Adi F Gazdar, John D Minna.   

Abstract

Lung cancer is the most common cause of cancer death in the United States, killing more than 156,000 people every year. In the past two decades, significant progress has been made in understanding the molecular and cellular pathogenesis of lung cancer. Abnormalities of proto-oncogenes, genetic and epigenetic changes of tumor suppressor genes, the role of angiogenesis in the multistage development of lung cancer, as well as detection of molecular abnormalities in preinvasive respiratory lesions, have recently come into focus. Efforts are ongoing to translate these findings into new clinical strategies for risk assessment, chemoprevention, early diagnosis, treatment selection, and prognosis and to provide new targets and methods of treatment for lung cancer patients. All these strategies should aid in reducing the number of newly diagnosed lung cancer cases and in increasing the survival and quality of life of patients with lung cancer.

Entities:  

Mesh:

Year:  2002        PMID: 11826285     DOI: 10.1146/annurev.physiol.64.081501.155828

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  49 in total

1.  miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.

Authors:  Hongwei Liang; Minghui Liu; Xin Yan; Yong Zhou; Wengong Wang; Xueliang Wang; Zheng Fu; Nan Wang; Suyang Zhang; Yanbo Wang; Ke Zen; Chen-Yu Zhang; Dongxia Hou; Jing Li; Xi Chen
Journal:  J Biol Chem       Date:  2014-11-12       Impact factor: 5.157

2.  The sociobiologic integrative model (SBIM): enhancing the integration of sociobehavioral, environmental, and biomolecular knowledge in urban health and disparities research.

Authors:  M Chris Gibbons; Malcolm Brock; Anthony J Alberg; Thomas Glass; Thomas A LaVeist; Stephen Baylin; David Levine; C Earl Fox
Journal:  J Urban Health       Date:  2007-03       Impact factor: 3.671

Review 3.  The pivotal role of pathology in the management of lung cancer.

Authors:  Morgan R Davidson; Adi F Gazdar; Belinda E Clarke
Journal:  J Thorac Dis       Date:  2013-10       Impact factor: 2.895

Review 4.  Role of DMP1 and its future in lung cancer diagnostics.

Authors:  Takayuki Sugiyama; Donna P Frazier; Pankaj Taneja; Rachel L Morgan; Mark C Willingham; Kazushi Inoue
Journal:  Expert Rev Mol Diagn       Date:  2008-07       Impact factor: 5.225

5.  MicroRNAs As Biomarkers For Clinical Features Of Lung Cancer.

Authors:  Roland Hubaux; Daiana D Becker-Santos; Katey S S Enfield; Stephen Lam; Wan L Lam; Victor D Martinez
Journal:  Metabolomics (Los Angel)       Date:  2012-03-21

6.  Selective requirements for E2f3 in the development and tumorigenicity of Rb-deficient chimeric tissues.

Authors:  Tiziana Parisi; Tina L Yuan; Ann Marie Faust; Alicia M Caron; Roderick Bronson; Jacqueline A Lees
Journal:  Mol Cell Biol       Date:  2007-01-08       Impact factor: 4.272

Review 7.  Gene Therapy for Lung Cancer.

Authors:  Humberto Lara-Guerra; Jack A Roth
Journal:  Crit Rev Oncog       Date:  2016

Review 8.  Lung cancer. 9: Molecular biology of lung cancer: clinical implications.

Authors:  K M Fong; Y Sekido; A F Gazdar; J D Minna
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

9.  Integrin expression profiling identifies integrin alpha5 and beta1 as prognostic factors in early stage non-small cell lung cancer.

Authors:  Anne-Marie C Dingemans; Vivian van den Boogaart; Bettine A Vosse; Robert-Jan van Suylen; Arjan W Griffioen; Victor L Thijssen
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

10.  Enzastaurin inhibits invasion and metastasis in lung cancer by diverse molecules.

Authors:  A Körner; G Mudduluru; C Manegold; H Allgayer
Journal:  Br J Cancer       Date:  2010-08-24       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.